Guidelines for Screening and Treatment of Stimulant Use Disorders

Screening Approaches

The American Academy of Pediatrics recommends that drug testing is not used as a general screening procedure for stimulant use in unselected populations due to low sensitivity 1
Integration of substance use disorder screening into routine care is recommended, particularly for high-risk populations, as suggested by the American Medical Association 2, 3

Evaluate the pattern, duration, and severity of stimulant use, including symptoms of dopamine depletion, and screen for co-occurring mental health conditions, as recommended by the American College of Cardiology 4, 5
Assess for medical complications of stimulant use, particularly cardiovascular issues, as stimulants can cause coronary artery spasm, tachycardia, and increased blood pressure, according to the American Heart Association 5

Contingency Management (CM) plus Community Reinforcement Approach (CRA) is the most effective treatment combination for stimulant use disorders, showing superior efficacy for improving morbidity, mortality, and quality of life outcomes, as recommended by the American Psychological Association 4, 5
Cognitive Behavioral Therapy (CBT) is recommended as an alternative when CM+CRA is not available, though it shows less efficacy, according to the American Psychiatric Association 4, 5
For patients with co-occurring opioid and stimulant use disorders, medications for opioid use disorder should be initiated without delay, as suggested by the American Medical Association 2, 3

Harm reduction services, including naloxone dispensation, safe use education, fentanyl test strips, and referral to syringe services, should be offered to all who report stimulant use, as recommended by the American Medical Association 2, 3
Innovative service delivery options, such as extended hours, mobile clinics, walk-in options, telehealth, and peer support, should be considered to improve retention in care, according to the American Public Health Association 2, 3

Patients with co-occurring ADHD require specialized treatment approaches to balance addressing underlying ADHD while avoiding stimulant medications that could trigger relapse, as recommended by the American Academy of Child and Adolescent Psychiatry 4
Stimulant withdrawal can present with fatigue, depression, and intense cravings, requiring supportive care and monitoring, according to the American College of Cardiology 4

Relying solely on drug testing without clinical context can lead to misdiagnosis, as standard laboratory tests may detect substances present but not causing observed symptoms, as warned by the American Academy of Pediatrics 1
Failing to recognize that stimulant use disorders frequently co-occur with other substance use and mental health disorders, requiring integrated treatment approaches, as emphasized by the American Medical Association 2, 3, 5
Using selective β1-blockers in patients who may continue to use cocaine can lead to unopposed α-adrenergic stimulation, as cautioned by the American Heart Association 5

Non-stimulants like atomoxetine, clonidine, or guanfacine may be considered as first-line treatment options for ADHD with comorbid substance use disorders, as recommended by the American Academy of Child and Adolescent Psychiatry 6, 7
When stimulant use disorder co-occurs with anxiety disorders or Tourette's syndrome, non-stimulant medications may be preferred, according to the Journal of the American Academy of Child and Adolescent Psychiatry 6, 8
For patients with comorbid depression, evaluation of whether depression or stimulant use is the primary disorder requiring initial focus is crucial, as suggested by the Journal of the American Academy of Child and Adolescent Psychiatry 8

When combined with pharmacotherapy, Cognitive Behavioral Therapy (CBT) should be favored over usual care to improve clinical outcomes, as recommended by the American Medical Association, according to a study published in 2020 9

All patients with stimulant use disorder should be asked about thoughts, plans, or acts of self-harm, as assessed by the National Institute of Mental Health, according to a study published in PLoS Medicine in 2011 10